Indimacis 125
Withdrawn
This medicine's authorisation has been withdrawn
igovomab
MedicineHumanWithdrawn
On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.
- Application under evaluation
- CHMP opinion
- European Commission decision
Overview
The marketing authorisation for Indimacis 125 has been withdrawn at the request of the marketing authorisation holder.
Product information
31/12/2009
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Product details
- Name of medicine
- Indimacis 125
- Active substance
- igovomab
- International non-proprietary name (INN) or common name
- igovomab
- Therapeutic area (MeSH)
- Radionuclide Imaging
- Ovarian Neoplasms
- Anatomical therapeutic chemical (ATC) code
- V09IB03
Pharmacotherapeutic group
Diagnostic radiopharmaceuticalsTherapeutic indication
Positive diagnosis of relapsing ovarian adenocarcinoma when serum CA 125 is increased without positive results of ultrasound or computerised tomography scan.
This page was last updated on